Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04214392 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04214392 · ClinicalTrials.gov record · last posted 2026-08-24

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Name: Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma — clinical trial record (NCT04214392)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorCity of Hope Medical Center

Started2020-02-26

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.

Protocol amendment history 2 changes detected by DataLookout

2026-08-25

Primary completion pushed: 2027-05-11 → 2027-08-20

2026-08-25

Completion pushed: 2027-05-11 → 2028-07-20

Trial Details

NCT Number	NCT04214392
Lead Sponsor	City of Hope Medical Center Collaborators: National Cancer Institute (NCI)
Conditions	Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
Enrollment	19 participants
Start Date	2020-02-26
Primary Completion	2027-08-20 (estimated)
Study Completion	2028-07-20 (estimated)
Updated on ClinicalTrials.gov	2026-08-24